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ABSTRACT
Resminostat, a novel class I, IIb, and IV histone deacetylase inhibitor, was 
studied in advanced hepatocellular carcinoma (HCC) patients after relapse to 
sorafenib (SHELTER study). In this phase I/II clinical trial, combination of sorafenib 
and resminostat was safe and showed early signs of efficacy. However, the molecular 
mechanisms behind this synergism have not been explored yet. In this work, we 
aimed to analyze whether resminostat regulates epithelial-mesenchymal and 
stemness phenotype as a mechanism of sensitization to sorafenib. Three HCC cell 
lines with differences in their epithelial/mesenchymal characteristics were treated 
with resminostat and sorafenib alone, or in combination. Resminostat prevented 
growth and induced cell death in the HCC cells, in a time and dose dependent 
manner. A collaborative effect between resminostat and sorafenib was detected in 
the mesenchymal HCC cells, which were insensitive to sorafenib-induced apoptosis. 
Expression of mesenchymal-related genes was decreased in resminostat-treated HCC 
cells, concomitant with an increase in epithelial-related gene expression, organized 
tight junctions and reduced invasive growth. Moreover, resminostat down-regulated 
CD44 expression, coincident with decreased capacity to form colonies at low cell 
density. Conclusion: Resminostat shifts mesenchymal cells towards a more epithelial 
phenotype, lower invasive and stemness properties, which may contribute to the 
sensitization to sorafenib-induced apoptosis.
INTRODUCTION
Human hepatocellular carcinoma (HCC) is the 
second most common cause of cancer-related death in 
men worldwide with increasing incidence [1]. Currently, 
sorafenib, a multikinase inhibitor, is the only approved 
drug for patients with advanced HCC, providing survival 
advantage of 3-months over the non-treated group [2]. 
Primary or acquired resistance is frequent. Therefore, 
novel therapies are needed for patients with advanced 
HCC after the failure of sorafenib.
Recent evidences pointed out that apart from an 
accumulation of genetic alterations of tumor-suppressor 
genes and oncogenes, epigenetic processes play an 
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important role in HCC development [3, 4]. Histone 
deacetylases (HDACs) modulate gene expression by 
enzymatic removal of acetyl groups from lysine residues 
in both histones and other proteins. 18 HDACs have been 
identified so far and classified into four groups: the class I 
HDACs (HDAC1, 2, 3 and 8), class IIa HDACs (HDAC4, 
5, 7, 9), class IIb HDACs (HDAC6 and 10), class III 
HDACs (sirtuins) and class IV HDACs (HDAC11). 
Inhibitors of HDACs are attractive epigenetic modulating 
agents due to low toxicity and frequent upregulation 
of HDACs in cancers. Specifically in HCC, HDAC1 
expression was reported to be directly correlated with 
aggressiveness and could be used as a prognostic factor 
in patients with HCC after surgery [5]. As a consequence, 
down-regulation of HDAC1 was suggested as a novel 
treatment strategy in HCC [6]. Importantly, HDAC1 
downregulation by sh-RNA [6] or by a specific inhibitor 
[7] showed low toxicity to normal hepatocytes. Other 
HDACs were also found to be up-regulated in HCC, such 
as HDAC2 [8] or HDAC3 [9, 10].
Resminostat is a novel orally available HDAC 
inhibitor, inhibiting classes I, IIb and IV of HDACs. The 
efficacy of resminostat in vitro was first evaluated in 
multiple myeloma cells. Inhibition of HDACs 1,3 and 
6 was demonstrated at nanomolar concentration and the 
efficacy to abrogate cell growth and to induce apoptosis 
at micromolar concentration [11]. Safety of resminostat 
and the recommended dose were evaluated in a phase I 
study in patients with advanced solid tumors [12] and 
confirmed in a group of Japanese patients [13]. The 
recently finished SHELTER study, a phase I/II clinical 
trial in patients no longer responding to sorafenib, 
compared the anti-tumor efficacy of resminostat alone 
or in combination with sorafenib. Safety of mono- 
and combination therapy was demonstrated and the 
combination therapy revealed an advantage in terms of 
overall survival and time to progression. Moreover, the 
transcription factor zinc finger protein 64 (ZFP64) was 
identified as a prognostic and putative predictive factor 
for overall survival [14]. In a follow-up study, a phase I/
II clinical trial of sorafenib alone or in combination with 
resminostat as first line therapy in Asian patients did 
not reveal overall survival benefits of the combination 
treatment. However, stratification of patients, based on 
HBV, platelet counts or non-prior treatment showed 
favourable results [15].
The molecular mechanism that could explain the 
synergism between resminostat and sorafenib has not been 
explored yet. In previous studies, we described that lack 
of response to sorafenib in HCC cells correlates with a 
mesenchymal phenotype and the expression of the stem-
related gene CD44 [16]. Therefore, here we performed 
an in vitro analysis of the effects of resminostat on the 
mesenchymal and stemness phenotype in HCC cells as a 
possible mechanism of sensitization to sorafenib-induced 
cell apoptosis.
RESULTS
HCC cells are sensitive to resminostat induced 
cell death
For this study we have selected three representative 
HCC cell lines with differences in their epithelial/
mesenchymal phenotype. We have selected an epithelial 
Hep3B cell line, with high expression of an epithelial 
marker E-cadherin and a marker of tight junctions, Zonula 
occludens-1 (ZO-1), organised in cell membranes. On the 
other hand, two mesenchymal HCC cell lines were used: 
HLE and HLF, with high expression of a mesenchymal 
marker vimentin and a presence of stress fibres (F-actin) 
(Figure 1A). A mesenchymal phenotype, characterised by 
low expression of E-cadherin (CDH1), high expression 
of vimentin (VIM) and high expression of EMT-inducing 
transcription factors, such as TWIST1, ZEB1, SNAI1 
and SNAI2 (Figure 1B) moreover correlates with the 
expression of cancer stem cell markers CD44 and CD90 
(Figure 1C). Correspondingly, the epithelial phenotype 
with high CDH1 expression, low expression of VIM and 
low expression of EMT-inducing transcription factors 
(Figure 1B) correlates with high expression of cancer stem 
cell markers CD133 and EPCAM (Figure 1C).
First, we analyzed the effect of resminostat (0-
10 μM) on cell viability in those three HCC cell lines 
by crystal violet staining. The cell lines exhibited 
dose-dependent sensitivities to the cytotoxic effects 
of resminostat, presenting IC50 of 5.9, 3.7 and 2.0 μM 
(Hep3B, HLE and HLF, respectively: Figure 2A). The 
analysis of the induction of cell death by resminostat 
revealed higher percentage of dead cells (PI-positive) in 
resminostat-treated cells, being the mesenchymal HLE and 
HLF the more sensitive at lower resminostat dosage (2.5 
μM) (Figure 2B and Supplementary Figure 1). Analysis of 
cell cycle after 24, 48 and 72 h of resminostat treatment (0-
2.5 μM) in HLF cells presented a dose and time dependent 
induction of subG1 cells, with only modest changes in 
other phases of the cell cycle (Figure 2C). The induction 
of subG1 phase was also observed in resminostat-treated 
Hep3B and HLE cells (Supplementary Figure 2).
Effect of combined treatment of resminostat and 
sorafenib in HCC cells
To examine the effect of the combined treatment 
on cell viability, Hep3B, HLE and HLF cells were treated 
with resminostat at low toxicity dose (1 μM) for 72 h. 
Later, cells that were not pre-treated with resminostat 
were maintained under control conditions or treated with 
sorafenib. Cells pre-treated with resminostat (1 μM) 
continued to be treated with resminostat (1 μM) or with 
a combination of resminostat (1 μM) and sorafenib (10 
μM) for up to 72 h and cell viability was determined by 
crystal violet staining. Our results revealed that in the 
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Figure 1: Characterization of HCC cell lines used in the study. (A). Immunofluorescence analysis of E-cadherin (green), ZO-1 
(green), vimentin (green), F-actin (red) and DAPI (blue). Scale bar =25 μm. (B+C). mRNA expression levels detected by qRT-PCR 
normalized to housekeeping gene L32. Mean±SD (n=3). (B). EMT-related genes CDH1, VIM and EMT-inducing transcription factors 
TWIST1, ZEB1, SNAI1 and SNAI2. (C). Stemnesss-related genes CD133, EPCAM, CD44 and CD90.
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mesenchymal HLE and HLF cells resminostat treatment 
enhanced sorafenib-induced decrease in cell viability, 
in a time-dependent manner (Figure 3A). More detailed 
analysis in HLF cells revealed that resminostat pre-
treatment was not necessary in order to observe the 
collaborative effect. Furthermore, the synergistic effect 
was observed even at lower sorafenib concentration (5 
μM) (Figure 3B). Considering this result, all the following 
experiments were performed at these concentrations and 
after simultaneous addition of both drugs.
To know whether the IC50 or resminostat changed 
in combination with sorafenib, we treated the Hep3B, HLE 
and HLF cells with sorafenib (5 μM) and resminostat in a 
range of concentrations (0-10 μM) (Supplementary Figure 
3). Worthy to note that the calculated IC50 of resminostat 
slightly decreased in combination with sorafenib (5 μM), 
being 4.9 μM for Hep3B, 2.1 μM for HLE and 1.5 μM 
for HLF cells. Next, we maintained Hep3B, HLE and 
HLF cells under control conditions (resminostat 0 μM) 
or treated with resminostat (1 μM), sorafenib (5 μM) 
or a combination of both and analyzed cell viability by 
crystal violet staining (Figure 4A). Interestingly, in HLE 
and HLF cells, where sorafenib arrested proliferation but 
did not induce loss of cell number (Supplementary Figure 
Figure 2: Response of HCC cells to resminostat treatment. (A). Hep3B, HLE and HLF were treated with resminostat (0-10 μM) 
for 72 h. Viable cells were analysed by crystal violet staining and normalised to control. Mean±SD (n=3). (B). Hep3B, HLE and HLF 
were treated with resminostat (0, 1, 2.5, and 5 μM) for 72 h. The % of non-viable cells (PI-positive) was determined by flow cytometry. 
Mean±SD (n=3). * p< 0.05, ** p<0.01, *** p<0.001 as compared to control. + p<0.05, ++ p<0.01, +++ p<0.001 as compared to Hep3B. (C). 
HLF cells were treated with resminostat (0, 1 and 2.5 μM) for 24, 48 and 72 h. 2x105 cells of respective samples were fixed with ethanol, 
and stained using PI for cell cycle analysis. Mean±SD (n=3). * p< 0.05, ** p<0.01, *** p<0.001.
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4), the combination of resminostat and sorafenib induced 
a significant enhancement of cell death (Figure 4B and 
Supplementary Figure 5). The analysis of cell cycle in 
HLF cells demonstrated an induction of subG1 phase 
(characteristic of apoptosis) with only modest changes in 
other phases of the cell cycle (Figure 4C). Furthermore, 
analysis of the cleavage of poly ADP ribose polymerase 
(PARP, target of caspase-3 during the apoptosis process), 
was higher in HLF cells treated with the combination of 
resminostat and sorafenib, as compared to resminostat 
treatment (Figure 4D). The cleaved form of PARP was 
barely detected after sorafenib treatment, which reinforced 
the lack of apoptosis response of these cells to sorafenib. 
These effects correlated with collaborative effects of 
resminostat and sorafenib in decreasing levels of pERKs, 
one of the well-known sorafenib targets (Supplementary 
Figure 6). At short time of sorafenib treatment, cells 
showed activated ERKs phosphorylation, as a mechanism 
of defence against the drug. In the presence of resminostat, 
this activation was abolished. Furthermore, at longer 
times, when sorafenib inhibits ERKs phosphorylation, 
the presence of resminostat amplified the effect. HDAC 
activity was efficiently inhibited by resminostat and the 
same degree of inhibition was observed in the presence of 
sorafenib (Supplementary Figure 6).
Figure 3: Pre-treatment with resminostat sensitizes mesenchymal HCC cells to sorafenib-induced apoptosis. (A). 
Hep3B, HLE, HLF cells were pre-treated without or with resminostat (1 μM) for 72 h. Cells pre-treated without resminostat were later 
treated without (Control) or with sorafenib (10 μM). Cells pre-treated with resminostat (1 μM) were later treated with resminostat (1 μM) 
or a combination of resminostat (1 μM) and sorafenib (10 μM). Viable cells were analyzed by crystal violet staining after 24, 48 and 72 h 
of respective treatments and normalized to control (resminostat 0 μM). Mean±SD (n=3). ** p<0.01, *** p<0.001. (B). HLF cells were pre-
treated in the absence (top graph) or in the presence of resminostat 1 μM (middle graph) for 72 h and later treated without (Control) or 
with resminostat (1 μM), sorafenib (5 μM) or a combination of resminostat (1 μM) and sorafenib (5 μM). Viable cells were analyzed by 
crystal violet staining after 24, 48 and 72 h of respective treatments and normalized to control (resminostat 0 μM). A comparison between 
the pre-treatment in the absence (black bars) and in the presence of resminostat (1 μM, white bars) is shown in the bottom graph. Mean±SD 
(n=3). *** p<0.001.
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Overall, here we have demonstrated that HCC 
cell lines respond to resminostat inducing cell death, 
which correlated with an apoptotic process. Moreover, 
a collaborative effect between resminostat and sorafenib 
is observed, particularly in the mesenchymal HLE and 
HLF cells that are poorly responsive to sorafenib in terms 
of apoptosis. Interestingly, the toxic effect of both drugs 
is lower in untransformed liver cells and no significant 
collaboration among them is observed (Supplementary 
Figure 7).
Figure 4: Effect of combined treatment with resminostat and sorafenib in HCC cells. (A+B). Hep3B, HLE and HLF cells 
were treated in the absence (Control) or in the presence of resminostat (1 μM), sorafenib (5 μM) or a combination of resminostat (1 μM) and 
sorafenib (5 μM) for 72 h. (A). Viable cells were analyzed by crystal violet staining after 72 h of respective treatments and normalized to 
control (resminostat 0 μM). Mean±SD (n=3). * p< 0.05, ** p<0.01, *** p<0.001. (B). The % of non-viable cells (PI-positive) was determined 
by flow cytometry. Mean±SD (n=3). * p< 0.05, ** p<0.01. (C). Representative images of cell cycle in HLF cells after combinatory treatment. 
(D). Western blot analysis of PARP and cleaved PARP in HLF cells after 48 h of respective treatments. β-actin was used as a loading control. 
Densitometry analysis is below respective bands and normalized to β-actin.
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Resminostat affects the expression of EMT-
related genes in HCC cells, which correlates 
with inhibition in their migratory and invasive 
properties
In previous studies, we described that a 
mesenchymal phenotype and the expression of the stem-
related gene CD44 confers lack of sensitivity to sorafenib-
induced apoptosis in HCC cells [16]. Therefore, next 
we decided to analyze the effect of resminostat on the 
mesenchymal and stemness phenotype.
Analysis of gene expression after 24 h of 
resminostat (1 μM) treatment in mesenchymal HLE 
and HLF cells revealed a shift towards an epithelial 
phenotype, even though to a different extent in each 
cell line. In HLE cells, resminostat treatment led to 
an up-regulation of CDH1 with a concomitant down-
regulation of EMT-inducing transcription factors TWIST1 
and SNAI2. In HLF cells we observed a tendency in 
CDH1 up-regulation and a significant down-regulation 
of VIM expression without downregulation of SNAI1 
or SNAI2 (Figure 5A). Western blot analysis revealed 
a tendency of increased E-cadherin expression and 
decreased vimentin expression (Figure 5B). Moreover, 
by immunofluorescence analysis we confirmed vimentin 
downregulation (Figure 5C). During EMT, cells lose the 
compact, well-arranged, epithelial structure and gain a 
spindle-like morphology. During this process, cells lose 
the expression of ZO-1 protein, among others, that is 
responsible for tight junctions between cells. Therefore, it 
was interesting to note that resminostat treatment in HLF 
cells increased the expression of ZO-1 and re-organised 
ZO-1 to cell membranes, suggesting a formation of 
tight junctions and cell clusters, and therefore a more 
epithelial phenotype. Indeed, when we analyzed the % 
of individual cells in 3D setting (embedded in collagen 
I), we could observe a decrease of individual cells and 
an increase of cells in cell clusters after resminostat 
treatment (Figure 5D). Similarly, mesenchymal 
phenotype is connected with higher migration and 
invasive capacities. We evaluated HLF cells treated with 
resminostat in an invasive growth assay, in which cells 
need to invade trough collagen I in a 3D setting. In fact, 
resminostat treatment decreased their invasive ability 
(Figure 5E and Supplementary Figure 8).
Resminostat down-regulates CD44 expression in 
HCC cells, which reduces their stemness capacity
Analysis of gene expression after 24 h of resminostat 
(1 μM) treatment in mesenchymal HLE and HLF cells 
revealed a downregulation of a stem cell marker related to 
a mesenchymal phenotype, CD44, in both cell lines (Figure 
6A). Furthermore, the ability of cells to grow in low dilutions 
(functional assay of stemness capacity) was significantly 
decreased by resminostat treatment (Figure 6B).
DISCUSSION
HCC is one of the most frequent cancers with more 
than 500,000 new cases observed each year with resistance 
to conventional chemo- and radiotherapy. Currently, 
sorafenib is standard of care for patients with advanced 
HCC, however up to 80% of patients suffer from side 
effects and even patients who initially respond to sorafenib 
develop resistance during therapy. The molecular 
mechanisms for the development of resistance are being 
extensively studied [17]. Therefore, the development of 
novel targeted therapy is needed. Emerging evidences 
suggest that frequent epigenetic alterations in HCC open 
new possibilities for therapeutic targeting [3, 4]. Although 
HDAC inhibitors showed antitumor efficacy in preclinical 
models, there was a lack of efficacy against solid tumors 
as monotherapy in clinical trials except for some 
hematological malignancies. HDAC inhibition will be 
probably most effective as part of combination therapies 
[18]. Indeed, the efficacy of resminostat, a novel orally 
available HDAC inhibitor, is being evaluated as a single 
agent or in combination with sorafenib in HCC [14, 15].
In this study we have demonstrated that resminostat 
is able to decrease the proliferation and viability in culture 
of different HCC cell lines in a dose-dependent manner. 
Mesenchymal HCC cell lines (such as HLE and HLF) 
were even more sensitive in terms of cell death.
To study the effect of co-treatment with resminostat 
and sorafenib, we used a low, non-toxic concentration 
of resminostat (1 μM). HDAC activity was efficiently 
inhibited by resminostat and this inhibition was 
maintained in the presence of sorafenib. Furthermore, 
co-treatment with resminostat and sorafenib had a 
higher impact on the decrease in p-ERKs levels (relevant 
targets of sorafenib) than that one exerted by each drug 
independently. Interestingly, we found a collaborative 
effect among these drugs, particularly in the mesenchymal 
HLE and HLF cells, previously identified as unresponsive 
to sorafenib in terms of apoptosis [16]. Indeed, percentage 
of hypodiploid cells and PARP cleavage (as hallmark of 
caspase activation) were higher in the combined treatment. 
Our results are in agreement with a recent study that 
demonstrate synergistic effects between resminostat and 
sorafenib in HCC cells [19]. Furthermore, a previous 
study using the HDAC inhibitor MPT0E028 also showed 
synergy with sorafenib in vitro and in vivo HCC models 
[20].
The association between EMT and sorafenib 
resistance, either as a trigger or as a result of treatment, 
was reported in various studies. A study by Zijl et al. 
demonstrated that mesenchymal HCC cell lines show 
higher resistance to cytotoxic drug, including sorafenib 
[21]. In a study by van Malenstein et al., long-term 
treatment of HCC cells with sorafenib lead to EMT with 
concomitant increased invasion, risk of rebound growth 
and resistance, phenomenon also observed in patients 
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[22]. Previous studies from our group demonstrated that 
the resistance to sorafenib is associated to a mesenchymal 
phenotype and expression of mesenchymal stem-related 
genes, in particular, CD44. Switching to an epithelial 
phenotype and down-regulation of CD44 sensitized the 
mesenchymal HCC cells to sorafenib [16].
Recent evidence suggested that cancer cells undergo 
dynamic and reversible transitions between multiple 
phenotypic states, ranging from a fully differentiated 
epithelial state to a dedifferentiated mesenchymal state. 
Importantly, the fully mesenchymal state is not permanent, 
as cells might revert to an epithelial state through a 
Figure 5: Resminostat affects the expression of EMT related genes. (A). HLE and HLF cells were treated with resminostat 
(1 μM) for 24 h. mRNA expression levels were detected by qRT-PCR, normalized to housekeeping gene L32 and to respective control 
(resminostat 0 μM). (B). Western blot analysis of E-cadherin and vimentin in HLF cells after 24 hours of resminostat (1 μM) treatment. 
β-actin was used as a loading control. Densitometry analysis is below respective bands and normalized to β-actin. (C). HLF cells were 
treated with resminostat (1 μM) for 24 h. Immunofluorescence analysis of vimentin (green), ZO-1 (green) and DAPI (blue). Scale bar = 25 
μm. (D). HLF cells were treated with resminostat (1 μM) for 72 h and seeded on top of a thick collagen I matrix. Left: Representative phase 
contrast images after 24 h (10x objective). Right: After 24 h, cells were stained using F-actin and DAPI, visualized by confocal microscopy 
and the % of individual cells was counted using ImageJ software. The % of individual cells is represented by a box plot with whiskers 
(min to max). Mann-Whitney t-test was used for statistical analysis. n=20 from a representative experiment. ** p<0.01. (E). HLF cells were 
treated with resminostat (1 μM) for 72 h and afterwards, the invasive growth in a Collagen I was analyzed. At respective times (0, 24, 48 
and 72 h) of the invasion assay, phase contrast images were taken and the area of formed spheroid was analyzed by ImageJ software. *** 
p<0.001. Mean±SD (n at least 20 spheroids).
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mesenchymal-epithelial transition (MET) [23]. The 
plasticity and reversibility of this process requires not only 
reprogramming of gene expression, but also epigenetic 
regulation [24].
Based on demonstrated evidence that the 
resistance to sorafenib in HCC could be a result of 
EMT processes and that epigenetics might play a role 
in EMT induction, we went on to analyse the effect of 
resminostat in the mesenchymal HLE and HLF cell lines 
in terms of induction of phenotypical changes. Indeed, 
gene expression analysis of EMT markers and EMT 
transcription factors confirmed that resminostat is able 
to shift cells towards a more epithelial phenotype, even 
though not to a complete epithelial state and to a different 
extend in each of the cell line analyzed. Furthermore, a 
marker of cell-cell junctions, ZO-1, was localized in the 
cell membranes after resminostat treatment, suggesting 
induction of an epithelial phenotype. Moreover, the % of 
individual cells after resminostat treatment was decreased, 
which suggests the increase in cell-cell junctions. A 
functional assay of invasive growth in 3D (collagen 
I) further demonstrated that the shift towards a more 
epithelial phenotype evidenced in resminostat-treated 
HLF cells provoked a significant decrease in their invasive 
capacities. Previous studies also would suggest that 
epigenetic modulation by HDACs affects the HCC cell 
phenotype. Indeed, downregulation of HDAC1 by shRNA 
led to an increase in the levels of ZO-1 and E-cadherin, 
a decrease in Vimentin and consequent suppression of 
migration [6]. Moreover, HDAC1 was observed to directly 
down-regulate ZO-1 and E-cadherin expression in HCC 
cells, and therefore there might be a possible linkage 
between HDAC1 overexpresssion and EMT-related 
invasiveness of HCC [25].
Accumulating evidence in HCC has demonstrated 
the existence of a small subset of cancer cells with 
properties of stem cells, such as self-renewal and 
differentiation. Importantly, the development of cancer 
recurrence, metastasis and resistance to conventional 
therapy is often attributed to the presence of cancer stem 
cells [26]. Increasing evidence suggests that epigenetic 
mechanisms play a role in the induction of cancer stem 
cells, and that targeting those mechanisms could induce 
differentiation and sensitize these cells to therapy [27]. 
The connection between EMT and stemness in cancer has 
been widely studied [28]. Indeed, here we are showing that 
the shift towards an epithelial phenotype by resminostat 
treatment correlates with downregulation of a cancer 
stem cell marker, CD44, and with a lower ability to form 
colonies (a functional assay of stemness capacity). We 
previously found a cross-talk between the Transforming 
Growth Factor (TGF)-β pathway and the acquisition of a 
mesenchymal-like phenotype with up-regulation of CD44 
expression in HCC cell lines, CD44 playing an active role 
in protecting these cells from sorafenib-induced apoptosis 
[16, 29]. Thus, a mesenchymal profile and high expression 
of CD44, linked to activation of the TGF-β pathway, may 
provoke lack of response to sorafenib in HCC patients. 
Here we propose that the effects of resminostat reversing 
this phenotype would favor the sensitization of these 
unresponsive cells to sorafenib-induced cell death.
In conclusion, resminostat prevents growth of HCC 
cells through the induction of cell death. In mesenchymal 
HCC cells, which are less sensitive to sorafenib, 
resminostat potentiates the response to sorafenib-
induced apoptosis. We demonstrate for the first time 
that resminostat induces a switch from a mesenchymal 
towards an epithelial phenotype and down-regulates 
CD44 expression, which correlates with lower invasive 
and stemness properties. This effect could justify the 
sensitization of mesenchymal HCC cells to sorafenib-
induced apoptosis.
Figure 6: Resminostat decreases CD44 expression and the stemness capacity of HCC cells. (A). HLE and HLF cells were 
treated with resminostat (1 μM) for 24 h. mRNA expression levels of CD44 were detected by qRT-PCR, normalized to housekeeping gene 
L32 and to respective controls (resminostat 0 μM). Mean±SD (n=3). ** p<0.01. (B). HLE and HLF cells were treated with resminostat (1 
μM) for 72 h. 500 cells were seeded in 2 mL of full media (containing 0 and 1 μM resminostat) in a 6-well-plate format. Left: Formed 




Hep3B cells were obtained from the European 
Collection of Cell Cultures (ECACC). HLE and HLF 
cells were from the Japanese Collection of Research 
Bioresources Cell Bank (JCRB Cell Bank). The human 
liver cell line CCL-13 (Chang liver, CHL) was from the 
American Type Culture Collection. Cell lines were never 
used in the laboratory for longer than four months after 
receipt or resuscitation. Characteristics of the HCC cell 
lines used are in Supplementary Materials and Methods. 
They were re-authenticated in 2014 by CLS (Cell 
Line Service, Eppelheim, Germany). Resminostat and 
sorafenib were prepared in dimethyl sulfoxide (DMSO) 
and diluted to working concentration (0-10 μM). 
Control condition always contained the same amount 
of DMSO as respective samples. Cells were maintained 
in DMEM media from Lonza (Basel, Switzerland) 
supplemented with 10% fetal bovine serum (FBS) from 
Sera Laboratories International (Cinder Hill, UK, GB), 
Penicillin (100 U/mL), Streptomycin (100 μg/mL), 
Amphotericin (2.5 μg/mL) and L-glutamine (2 mM), 
and were maintained in a humidified atmosphere at 37ºC, 
5% CO2. Cells were observed under an Olympus 70iX 
microscope and photographed with a Spot 4.3 digital 
camera. When cells were cultured on thick layers of 
collagen I, fibrillar bovine dermal collagen I (no. 5005; 
PureCol, Advanced BioMatrix) was prepared at 1.7 mg/
mL in DMEM according to the manufacturer’s protocol. 
After collagen I polymerization (4 h at 37ºC, 10% CO2) 
cells were seeded on top of the collagen in medium 
containing 10% FBS and allowed to adhere for 24 h.
Cell proliferation assay
Cells were seeded in a 24-well plate (15 000 cells/
well) in 500 μL of full DMEM supplemented with 10% 
FBS. After 24 h, the media was replaced with media 
containing respective compounds. At specific time 
points (0, 24, 48 and 72 h), cells were washed with PBS 
and stained with crystal violet (0.2% crystal violet in 
2% ethanol solution) for 30 min and later washed with 
distilled water and dissolved in 10% SDS on a shaker for 
30 min. The absorbance was analyzed on a plate reader at 
560 nm.
Analysis of cell death
After respective treatments, media (including 
floating cells) and remaining cells were collected and 
centrifuge at 1,200 rpm for 5 min at room temperature. 
The cell pellet was resuspended in 200 μL of PBS. 
Propidium Iodide (PI) at a final concentration of 1 μg/
ml was added to the samples and immediately analyzed 
by flow cytometry (Gallios flow cytometer by Beckman-
Coulter). Results were analyzed with Beckman Coulter’s 
Kaluza flow cytometry analysis software (version 1.1).
Flow cytometric analysis of cell cycle and 
apoptosis
After respective treatments, media (including any 
floating cells) and all remaining cells were collected. 2x105 
cells/sample were fixed with 70% ice-cold ethanol for 2 
min while vortexing. Samples were centrifuged at 2,500 
rpm for 5 min at 4°C. The cell pellet was resuspended 
in 200 μL of PBS, RNAse A at a final concentration of 
30 ng/mL (Sigma-Aldrich) was added and samples were 
cultivated for 30 min at 37°C. PI at a final concentration 
of 1 μg/mL was added to the samples 15 min prior analysis 
by flow cytometry (Beckman-Coulter). Results were 
analyzed with Beckman Coulter’s Kaluza flow cytometry 
analysis software (version 1.1).
Colony formation at low cell densities
After respective treatments, 500 cells were seeded in 
each well of a 6-well dish in triplicates in 2 mL of full media 
and were allowed to grow into colonies. After 12 days, 
colonies were stained with a solution of crystal violet (0.2% 
in 2% ethanol) and counted using ImageJ software and are 
represented as a number of colonies formed per well.
Invasive growth assays
Cells were resuspended in low viscosity media 
containing respective treatments (detailed in figure legend) 
in a concentration of 4x105 cells/mL and suspended 
as hanging drops for 72 h at 37ºC (5% CO2), to cluster 
into spheroids. Then, spheroids were resuspended in a 
solution of collagen I (1.7 mg/mL in DMEM, containing 
respective treatments) and incubated at 37ºC (10% CO2). 
Phase contrast pictures were taken at 0, 24, 48 and 72 h. 
For quantification, the area occupied by spheroids was 
calculated using ImageJ software.
Immunofluorescence studies in 2D
Fluorescence microscopy studies were performed 
as described previously [30]. Additional information 
and list of used antibodies in Supplementary Materials 
and Methods. Cells were visualized with a Nikon eclipse 
80i microscope. Representative images were taken with 
a Nikon DS-Ri1 digital camera and edited in Adobe 
Photoshop.
Immunofluorescence in cells cultured on thick 
layers of collagen I
Immunostaining of cells seeded on top of a thick 
collagen I matrix was performed as described previously 
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[31]. Additional information and list of used antibodies in 
Supplementary Materials and Methods. For the imaging, 
collagen gels with immunostained cells were transferred 
to glass-bottomed dishes and visualized on a Zeiss 
LSM 510 Meta confocal microscope (Carl Zeiss) with 
C-Apochromat 40x / 1.2 NA (water) and Zen software 
(Carl Zeiss). Confocal Z-slice images were analysed using 
ImageJ.
Western blot analysis
Procedure was carried out as described previously 
[30]. Additional information and list of used antibodies in 
Supplementary Materials and Methods.
Analysis of histone deacetylase activity
HDAC activity was analyzed by a fluorometric 
assay kit (Abcam, ab156064) according to manufacturer’s 
instructions.
Analysis of gene expression
RNeasy Mini Kit (Qiagen, Valencia, CA) was 
used for total RNA isolation. Reverse transcription was 
done using the High Capacity Reverse Transcriptase 
kit (Applied Biosystems, Foster City, CA, USA), and 1 
μg of total RNA from each sample for complementary 
DNA synthesis. For qRT-PCR, expression levels were 
determined in duplicate in a LightCycler 480 Real-time 
PCR system, using the LightCycler 480 SYBR Green 
I Master Mix (Roche Diagnostics GmbH, Mannheim, 
Germany). Human specific primers designed by Integrated 
DNA Technologies (IDT) are listed in Supplementary 
Materials and Methods.
Statistical analyses
All data represent at least three experiments and 
are expressed as the mean ± standard deviation (SD). 
Differences between groups were compared using either 
Student’s t-test assuming parametric distribution and by 
Mann-Whitney t-test assuming nonparametric distribution. 
Statistical significance was assumed when p<0.05. In 
all cases statistical calculation was performed using 
GraphPad Prizm software (Graph-Pad for Science Inc., 
San Diego, CA, USA).
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